Insurers Aren’t Convinced Obesity Drugs Are Worth It
The payment fight over weight loss drugs is at a fever pitch
Illustration: 731. Photo: Wegovy
Welcome to Bw Daily, the Bloomberg Businessweek newsletter, where we’ll bring you interesting voices, great reporting and the magazine’s usual charm every weekday. Let us know what you think by emailing our editor here! If this has been forwarded to you, click here to sign up.
You’ve seen them on TV ads and TikTok, or heard them joked about at the Oscars: Ozempic, Wegovy, Mounjaro. They’re weekly injections known as GLP-1 receptor agonists that help people lose a significant chunk of their body weight. These drugs can indeed produce dramatic results. But do they make people healthier?